| خلاصه مقاله | Introduction
Oxybutynin is an antimuscarinic utilized as a treatment for overactive bladder. This study aims to investigate the effects of oxybutynin on cognitive function.
Methods
Following the PRISMA statement, clinical trials which assessed the cognitive effects of oxybutynin in cognitively-intact individuals were included. A systematic search was conducted through Embase, PubMed, Cochrane, Scopus, and WoS with “Oxybutynin” and “cognition, memory, attention, executive function, learning”. The risk of bias was assessed using the JBI checklists.
Results
Out of 843 records, 8 studies including 7 RCTs, met our inclusion criteria. The overall quality of the studies was low. In comparison to the placebo, the oral form of oxybutynin did not affect the information process speed (IPS), attention and short-term, immediate and delayed memory based on trail-making tests, d2 attention test, developmental neuropsychological assessment, Buschke style word-list task, digit span, digit symbol, verbal fluency, finger tapping, reaction-time (RT), pattern recognition, name–face Association (NFA), and Hopkins verbal learning tests in six studies. The cognitive effects of immediate-released oxybutynin were evident in one study regarding the attention and alternates parameters. An extended-release form of oxybutynin was found to significantly affect delayed recall on the NFA and First–Last Name Association, and Misplaced Objects Tests, in one study; however, visual attention, IPS, RT, and self-rated memory were not affected.
Conclusions
The limited available evidence, suggests cognitive effects of only the extended-release form of oxybutynin. |